{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:42:47Z","timestamp":1773787367025,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":265,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Case Reports in Oncological Medicine"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    Colitis is a common side effect of all currently approved immune checkpoint inhibitors (ICIs). Vedolizumab is an\n                    <jats:italic>\u03b1<\/jats:italic>\n                    <jats:sub>4<\/jats:sub>\n                    <jats:italic>\u03b2<\/jats:italic>\n                    <jats:sub>7<\/jats:sub>\n                    monoclonal antibody approved for treating inflammatory bowel disease (IBD) and is commonly used off\u2010label to manage checkpoint inhibitor colitis (CIC). Previous studies have attempted dose escalation of vedolizumab for clinically unresponsive IBD patients and have been able to achieve clinical remission in 49.6% of these patients without an associated increase in adverse events. However, this has yet to be reported in patients with CIC. Here, we report on two patients who developed CIC after being treated with ICIs for metastatic cancer and received a double dose of vedolizumab. Both patients\u2019 colitis was initially treated with infliximab, steroids, and standard 300\u2010mg vedolizumab dosage with an incomplete response. When administered a double dose of 600\u2010mg vedolizumab, colitis symptoms were resolved without further recurrence or the need for treatment in both patients. This case series outlines effective clinical experience in treating patients with CIC refractory to standard vedolizumab dosage and supports further study of vedolizumab dose escalation in this patient population.\n                  <\/jats:p>","DOI":"10.1155\/crom\/7637337","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T12:05:27Z","timestamp":1758629127000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vedolizumab Dose Escalation Resolves Immune Checkpoint Inhibitor\u2013Induced Colitis in Two Patients"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3681-6245","authenticated-orcid":false,"given":"Cong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1416-089X","authenticated-orcid":false,"given":"Nikhil","family":"Nayee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-7889","authenticated-orcid":false,"given":"Jacqueline M.","family":"Garrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-9387","authenticated-orcid":false,"given":"Justin","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"e_1_2_13_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411504"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.001"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6138-7"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx081"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_13_11_2","unstructured":"Takeda Pharmaceuticals ENTYVIO (Vedolizumab) U.S. Food and Drug Administration website accessed October 2024 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125476Orig1s046lbl.pdf."},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000892"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.612830"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619873784"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz029"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14548"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002229"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)30608-X"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(16)30859-9"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2018.06.001"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14167"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15294"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otac020"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac200"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.5414\/cpp48297"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.13097"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2019-101197"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab067"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy272"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.040"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2022.0699"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1039121"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595835"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.84261"}],"container-title":["Case Reports in Oncological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crom\/7637337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/crom\/7637337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/crom\/7637337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:02:54Z","timestamp":1773774174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/crom\/7637337"}},"subtitle":[],"editor":[{"given":"Jose I.","family":"Mayordomo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/crom\/7637337"],"URL":"https:\/\/doi.org\/10.1155\/crom\/7637337","archive":["Portico"],"relation":{},"ISSN":["2090-6706","2090-6714"],"issn-type":[{"value":"2090-6706","type":"print"},{"value":"2090-6714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"7637337"}}